We often talk about the increase in AGEs (Advanced Glycation Endproducts) in patients with diabetes. We mainly think about these AGE’s in the development of vascular injury in our diabetes patients. However, the collagen in our joints is also subject to glycosylation and this means that many of our diabetes patients lose flexibility as they age and physical activity becomes very difficult. Dr. Sheri Colberg discuses this and how your patients can win back that flexibility in her monthly contribution, The Best Physical Activities to Do for Diabetes (and Life). This idea of selecting the right physical exercises can even benefit your patients by reducing the risk of developing Alzheimer’s disease 50% by reducing the formation of AGE’s.
In the race to be the third drug to market in the SGLT-2 inhibitor class, Lilly/BI was dealt a setback when the FDA declined to approve empagliflozin. Interestingly this had nothing to do with the drug or side effects and the FDA did not ask for any new clinical studies. The FDA had a concern with continued problems at BI’s manufacturing facility. I would have liked to be on the phone when the big cheese at Lilly made a call over to BI. I bet someone is scrubbing floors and washing walls this weekend.
Dave Joffe, Editor-in-chief